Vanda Pharmaceuticals Inc. (VNDA)

Market Cap	294.02M
Revenue (ttm)	192.64M
Net Income (ttm)	2.51M
Shares Out	57.54M
EPS (ttm)	0.04
PE Ratio	127.75
Forward PE	30.30
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,437,968
Open	4.94
Previous Close	4.97
Day's Range	4.93 - 5.30
52-Week Range	3.30 - 7.00
Beta	0.78
Analysts	n/a
Price Target	n/a
Earnings Date	May 1, 2024

About VNDA

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bi...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 12, 2006
• Employees: 203
• Stock Exchange: NASDAQ
• Ticker Symbol: VNDA

Financial Performance

In 2023, VNDA's revenue was $192.64 million, a decrease of -24.27% compared to the previous year's $254.38 million. Earnings were $2.51 million, a decrease of -60.02%.